Overview
- After a roughly 57% weekly surge, HIMS traded down about 3% Monday to $23.95 following a monthlong run.
- The renewed Novo partnership will replace most compounded GLP-1 offerings with Wegovy and Ozempic, with compounding limited to clinically necessary cases.
- Deutsche Bank lifted its target to $28 (neutral) as Citigroup moved to $24 and Bank of America to $23 with rating upgrades to neutral.
- Barclays last week reiterated Overweight and raised its price target to $29, reinforcing optimism around Hims & Hers’ weight-loss and wellness push.
- Recent updates highlight 49% revenue growth to $599 million, 2.5 million subscribers with $80 ARPU, margin compression from reinvestment, and a new subscriber benefits program with partner discounts.